<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gordon, Debra</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Haller, Hermann</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Early Treatment with Olmesartan Delays Progression of Nephropathy in Patients with Type 2 Diabetes</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">26-27</style></pages><abstract><style  face="normal" font="default" size="100%">The Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention [ROADMAP; NCT00185159] study investigated whether early administration of an angiotensin receptor blocker to diabetic patients with normal albumin excretion could delay or prevent the first occurrence of microalbuminuria and whether it could affect the incidence of cardiovascular and renal events.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>